Patent application number | Description | Published |
20110236478 | CO-CRYSTALS AND PHARMACEUTICAL FORMULATIONS COMPRISING THE SAME - An immediate release formulation of an active ingredient. | 09-29-2011 |
20120014912 | PALATABLE PHARMACEUTICAL COMPOSITION - A pharmaceutical formulation comprising:
| 01-19-2012 |
20120064157 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders and mini-tablets and methods for treating cystic fibrosis employing the pharmaceutical composition. | 03-15-2012 |
20130072440 | CO-CRYSTALS AND PHARMACEUTICAL FORMULATIONS COMPRISING THE SAME - The pharmaceutical composition including a co-crystal. The co-crystal includes a) a co-former; and b) an active pharmaceutical ingredient (API) with solubility in water is less than one part by weight of the API in ten parts by weight of water. Furthermore, the formulation includes a polymer, and a weight ratio of the co-crystal to the polymer is about 0.5:99.5 to about 99.5:0.5. The kinetic solubility of the co-crystal after being in contact with an environment of use is at a therapeutically acceptable level for a prolonged period of time. | 03-21-2013 |
20130195797 | HIGH POTENCY FORMULATIONS OF VX-950 - High potency pharmaceutical compositions comprising VX-950, sodium lauryl sulfate and a polymer selected from the group consisting of hypromellose acetate succinate-M, hypromellose acetate succinate-L and hypromellose acetate succinate-H. | 08-01-2013 |
20130224293 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N—[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 08-29-2013 |
20140255483 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 09-11-2014 |
20150024047 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. | 01-22-2015 |